Another Cuban COVID-19 vaccine candidate goes to phase II of clinical trials
The Cuban Abdala COVID-19 vaccine candidate will begin the second phase of clinical trials on February 1, the official media reported. In this way, the also named CIGB 66 will become the second vaccine project produced on the island to move to this phase of studies, after Soberana 02 did it last December. Phase II of the trial will be carried out at the Saturnino Lora Hospital in Santiago de Cuba, where the first stage of human trials has already been carried out. The new phase “will begin with the prior approval of the Center for State Control of Medicines, Equipment and Medical Devices (CECMED) and neutral provincial and national independent observers, as they don’t belong to the Saturnino Lora Hospital or the Center for Genetic Engineering and Biotechnology (CIGB), the creator of Abdala,” according to a report from the Agencia Cubana de Noticias (ACN) news agency. Now around 800 volunteers will participate in the next step of the study, who come from work and student centers in the city of Santiago, “in order to guarantee better control and permanence in the research,” according to Dr. Rafael Suárez, director of the hospital. Participants will be between 19 and 80 years...